 HIGH POINT, N.C., Dec. 15, 2020 GLOBE NEWSWIRE -- vTv Therapeutics Inc. Nasdaq:VTVT today announced that vTv Therapeutics LLC vTv has entered into a licensing agreement with Anteris Bio for worldwide rights to vTvs novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a newly-formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research NIBR Dr. Mark Fishman, will focus on developing HPP971 as a new therapy for the treatment of renal disease. 